Citations 2
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026
Spratt, Daniel E., Srinivas, Sandy, Ahmed, Bilawal, An, Yi , Bitting, Rhonda, Chapin, Brian, Cheng, Heather H., D’Amico, Anthony Victor, Desai, Neil, Dorff, T. B., Eastham, James A., Farrington, Thomas A., Gao, Xin, Gupta, S, Karnes, R. Jeffrey, Kishan, Amar U., Kuettel, Michael, Lang, J., Lee, Daniel, Lotan, Tamara, McDonald, Andrew, Morgan, Todd M. , Pessoa, Rodrigo, ROACH, M, Robin, Tyler, Rosenfeld, Stan, Scarpato, Kristen R., Seibert, Tyler, Shabsigh, Ahmad, Szmulewitz, Russell, Tward, Jonathan, Valicenti, Richard, VanderWeele, David, Wong, J.K. , Kovách, E, Freedman-Cass, Deborah, Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Bitting, Rhonda L. , Chapin, Brian F. , Cheng, Heather H., Cho, Steve Y. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, Jeff , Gupta, Shilpa , Ippolito, Joseph E. , Kishan, Amar U. , McDonald, Andrew M. , Rais‐Bahrami, Soroush , Roach, Mack , Scarpato, Kristen R., Shabsigh, Ahmad , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , Valicenti, Richard K., VanderWeele, David James , Freedman-Cass, Deborah A.
Journal of the National Comprehensive Cancer Network | May 14, 2026 | Volume: 24 | Issue: 5 | Pages: 140-149
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel’s discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026
Cheng, Heather H., Goggins, Michael, Yurgelun, Matthew B. , Karlan, Beth Y., Norquist, Barbara S., Daly, MB, Pal, Tuya, AlHilli, Zahraa, Arun, Banu , Churpek, Jane, Colonna, Sarah, Domchek, Susan M., Escobar, Mauricio R., Friedman, S, Hagemann, Andrea, Hendrix, Ashley, Huo, Dezheng, Hutton, Mollie L., Kassem, Nawal , Kurian, Allison W., Laronga, Christine , Mak, Julie S, McDonnell, Kevin, Mersch, Jacqueline, Offit, Kenneth, Plichta, Jennifer K. , Rash, Dominique , Reiser, Gwen , Senter-Jamieson, Leigha, Shannon, K. McWeeney, Welborn, Jeanna, Wick, Myra , Wood, Marie , Darlow, Susan, Diwan, Zeenat, Dwyer, Mary, Churpek, Jane E. , Kurian, Allison W. , Kurian, Allison W , Plichta, Jennifer K , Churpek, Jane E , Churpek, Jane , Giri, Veda N. , Goggins, Michael, Karlan, Beth Y , Norquist, Barbara, Pal, Tuya , Al‐Hilli, Zahraa , Arun, Banu , Colonna, Sarah V. , Domchek, Susan M. , Fejerman, Laura , Hagemann, Andrea, Huo, Dezheng , Khan, Seema A. , Mak, Julie , Maxwell, Kara N. , McDonnell, Kevin , Merajver, Sofía D. , Mersch, Jacqueline A, Offit, Kenneth , Darlow, Susan
Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 2-10
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic counseling and testing; help guide decisions related to genetic testing; and facilitate a multidisciplinary approach in the comprehensive care of individuals at increased risk for hereditary breast, ovarian, pancreatic, and prostate cancer. The current guidelines focus primarily on assessment of pathogenic and likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants associated with increased risk of these cancers. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding screening for prostate cancer and pancreas cancer, as well as testing criteria for nonepithelial ovarian cancer.